Safety of Arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy

Capotondo, A., Cesani, M., Pepe, S., Fasano, Stefania ORCID: https://orcid.org/0000-0002-3696-7139, Gregori, S., Tononi, L., Venneri, M.A., Brambilla, Riccardo ORCID: https://orcid.org/0000-0003-3569-5706, Quattrini, A., Ballabio, A., Cosma, M. P., Naldini, L. and Biffi, A. 2007. Safety of Arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. Human Gene Therapy 18 (9) , pp. 821-836. 10.1089/hum.2007.048

Full text not available from this repository.

Abstract

Successful gene therapy approaches for metachromatic leukodystrophy (MLD), based either on hematopoietic stem/progenitor cells (HSPCs) or direct central nervous system (CNS) gene transfer, highlighted a requirement for high levels of arylsulfatase A (ARSA) expression to achieve correction of disease manifestations in the mouse model. Full assessment of the safety of ARSA expression above physiological levels thus represents a prerequisite for clinical translation of these approaches. Here, using lentiviral vectors (LVs), we generated two relevant models for the stringent evaluation of the consequences of ARSA overexpression in transduced cells. We first demonstrated that ARSA overexpression in human HSPCs does not affect their clonogenic and multilineage differentiation capacities in clonogenic assays and in a neonatal hematochimeric mouse model. Further, we studied ARSA overexpression in all body tissues by generating transgenic mice overexpressing the ARSA enzyme by LV up to 15-fold above the normal range and carrying multiple copies of LV in their genome. Characterization of these mice demonstrated the safety of ARSA overexpression in two main gene therapy targets, HSPCs and neurons, with maintenance of the complex functions of the hematopoietic and nervous system in the presence of supraphysiological enzyme levels. The activity of other sulfatases dependent on the same common activator, sulfatase-modifying factor-1 (SUMF1), was tested in ARSA-overexpressing HSPCs and in transgenic mice, excluding the occurrence of saturation phenomena. Overall, these data indicate that from the perspective of clinical translation, therapeutic levels of ARSA overexpression can be safely achieved. Further, they demonstrate an experimental platform for the preclinical assessment of the safety of new gene therapy approaches.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	Mary Ann Liebert
ISSN:	1043-0342
Date of Acceptance:	31 July 2007
Last Modified:	27 Oct 2022 08:26
URI:	https://orca.cardiff.ac.uk/id/eprint/62306

Citation Data

Cited 40 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item